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enormous efforts from medical physicists to optimize planning, 
delivery and particularly in-room imaging to fully profit from the 
theoretical advantages of hadrontherapy. But also numerous, albeit 
less spectacular, problems have to be solved when implementing 
improved photon therapy options such as advanced IMRT, SRS, and 
VMAT techniques including the use of new in-room imaging and 
dosimetry procedures. Furthermore, integration of time in planning 
and delivery has resulted in a shift from viewing the patient as a static 
rigid body towards a dynamic non-rigid entity. However, the current 
tools for the plan-of-the-day approach are not ideal and new 
automated and fast procedures for 4D planning, dose verification and 
in-room imaging can therefore be expected the coming period.  
Implementing advanced technology in radiotherapy needs the 
expertise from radiation oncologists, physicists and RTTs. There is 
however a delay in implementing advanced technology tools due to 
the lack of time these staff members have to become familiar with 
these new devices and procedures.  Because many aspects of using 
new technology are at the interface between research and routine 
clinical work, there is a special role of medical physicists in 
introducing these tools. Investigating problems related to the use of 
new technology requires a research approach of a medical physicist. 
However, an academic attitude to find a perfect solution is often not 
possible in a busy clinic. Many issues fight for priority such as high 
quality versus simplicity, accuracy versus complexity and specificity 
versus an overall solution. On the other hand, a considerable part of 
the routine clinical work of medical physicists such as QA 
measurements can be performed by people not having a PhD.   
In order to implement new treatment approaches in radiotherapy it is 
necessary to design a working environment in which it is easy for staff 
to become familiar with advanced technology. Furthermore, it can be 
expected that only those advanced technology solutions that are 
robust and simple have a chance to be implemented at a large scale in 
the clinic. More attention should therefore be paid to “translating” 
new technological findings into practical approaches that can be 
implemented in centers having limited resources. To select patient 
groups for which these advanced technology tools are particularly 
beneficial is another challenge the coming era. In all these processes 
medical physicists can and should play a vital role. 
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Starting my training at the Barmherzige Schwestern Hospital in Linz, 
Austria, in 1973 all Radium-LDR applications were performed by the 
gynecologists. At the Department of Radiation Oncology no 
brachytherapy was used. My first contact with LDR wires was in 1978. 
This was at the Inselspital Bern, Switzerland, with Prof. Dr. Veraguth, 
precisely in June and July 1978. His specialty was the head & neck 
region. A year later I spent 3 months at the MD Anderson Cancer 
Center, primarily at the Section of Experimental Radiotherapy. But I 
had the opportunity to accompany Prof. Luis Delclos, the 
brachytherapist at this institution. Applications were limited to the 
uterus and the vagina using Radium insertions, and to prostate cancer 
using permanent Gold seed implants. Again a year later I spent 3 
months at the University Clinic in Freiburg/Breisgau, Germany, to 
learn about Iodine seed implantations. Only 2 months later I 
introduced this method at my hospital in Linz, Austria, in cooperation 
with our urologists. A year later, in 1982, I attended the 
brachytherapy course in Leeds, organized by Dan Ash. And in the same 
year I spent several weeks at Prof. Bernard Pierquin’s department in 
Creteil, France, to be introduced to the LDR wire implantations in 
breast cancer patients. Immediately we started with this method in 
Linz.  
In 1980 we changed to a HDR source, only suited for gynecological 
tumours and in 1984 to a tiny source suited for interstitial implants. 
From this time on we performed HDR breast boosts, in the same 
manner like Dr. Jacobs from Saarbrücken, Germany. The short 
radiation time of 45 to 60 minutes was a significant advantage 
compared to up to several days in LDR wire implants. The localization 
of the tumour bed in the breast was difficult at this time. We could 
orient ourselves only by means of mammography, surgery reports and 
the scar. In 1991 we acquired our first treatment planning CT so that 
we could define the tumour bed precisely and could verify the correct 
position of the needles, enabling us to correct these positions if 
necessary. In 1997 we added applications to bronchus, esophagus and 
anal canal to our routine portfolio, mostly as a boost to external beam 
treatments. Seldom cases were implants into the lip, cheek, vocal 
cord, vaginal, rectal and anal recurrences, etc., in part as a boost and 
in part as a primary treatment. 
At the beginning of the HDR era I was criticized by renowned 
radiotherapists and radiobiologists. They predicted severe side effects 
of the implanted tissues and surroundings, in particular the breast, 
going as far as necrosis of the entire organ. We therefore started to 
follow up the patients in relative short intervals, resulting in a data 
set of more than 1000 breast boost patients (1984 to 2008). We 
noticed no severe side effects. In the course of the years the local 
recurrence rate dropped, very slowly but steadily. In the first two 
years we observed some telangiectasia and skin fibroses after needle 
implants too close to the skin. As a consequence we applied Iridium-
HDR-implants only in patients with deep seated tumours. Experience 
showed that the 10 Gy isodose should have a distance of at least 
15mm from the skin to spare late side effects. The cosmetic results 
are excellent and depend on primary tumour size, size of the implant 
and tumor bed location. 
With increasing numbers of patients in our data set we performed 
several studies. The results showed a high relevance of the node ratio 
and the PR negative status. Also tumour location resulted in 
significant differences in terms of local control and survival. In many 
breast trials and studies these factors are not mentioned as negative 
prognostic factors. 
Brachytherapy provides a wide range of activities in many regions as a 
primary treatment or as a boost to EBRT in many entities. Together 
with modern imaging methods highly conformal applications by 
interventional radiotherapy became possible with the advantage of 
the application of high curative doses and a relevant reduction of side 
effects to the surrounding tissues (e.g. in APBI trials). 
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Since its inception in the 1950s, the TNM stage classification has 
provided a language to describe anatomic extent of disease in 
jurisdictions across the world. TNM serves several important purposes 
in cancer control and treatment: these include assisting in the 
planning of treatment, evaluation of prognosis, exchange of 
information about cancer, and contributing to research and cancer 
control throughout the world. For these reason it is essential to the 
activities of numerous domains involved in clinical trials, registry and 
surveillance, education, and guideline development for many 
cancers. Generally, and this includes for head and neck malignancies, 
it has also become synonymous with prognosis. However TNM also has 
significant limitations that include an inability to describe biology or 
to fully predict response to treatments, especially chemotherapy and 
targeted therapies. At the same time the success of TNM seems to 
have compelled the oncology community to try to embed other 
prognostic information within it as one of the few models to convey 
prognosis and prediction. Therefore a major challenge today is the 
integration of non-anatomic factors with anatomic in a way that is 
meaningful and robust so that accurate and effective tools become 
available to guide individualized care.  If a strategy is not developed 
the danger is that neither will be addressed properly and activities 
requiring one dimension of knowledge (e.g. extent of disease for 
cancer registry and essential tumor assessment in the clinic) will 
potentially be compromised or diverse patient groups previously 
considered as similar (e.g. patients with hypoxic tumors or those with 
an entirely different disease such as HPV-driven cancers) will not be 
effectively stratified to deliver tailored treatments where they may 
be beneficial. At present the UICC and the AJCC are developing a 
framework for clinical use that acknowledges the description of 
extent of disease but also biological and pathological characteristics 
of the tumor and the host to permit inclusion of validated non-
anatomic prognostic and predictive factors, especially biomarkers, 
that may guide treatment. This will involve agreement on a lexicon of 
terms and criteria for classification into appropriate risk groups in 
models that will include factors relevant to the disease setting. 
Important for the latter will be application of essential 
epidemiological principles that address the nature of the disease (e.g. 
primary vs recurrent disease, early vs advanced presentations, the 
type of treatment being considered, and in some cases the end-point 
being addressed within a given risk model). New terms are required to 
enhance this process, and existing definitions in data structures such 
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as those of the Cancer Data Standards Registry and Repository (caDSR) 
need to be adopted more widely to ensure uniformity. For a given 
biomarker, a classification needs to include the type of marker 
(whether diagnostic, prognostic, predictive, or companion diagnostic), 
the marker’s characteristics (e.g. what it is measuring in terms of 
pathways, or receptor status, at the molecular level), the physiologic 
compartment source (e.g. blood, urine, tissue, CSF, bone marrow), 
and the setting including clinical presentation and scenario specificity 
(i.e. when the marker is useful and relevant).  For the latter the 
decision will also need to address whether new diseases (e.g. HPV-
driven cancer) should continue to be combined with the classic 
version of oropharyngeal cancer since emerging data has underlined 
the separate nature of these processes at the etiology, clinical, 
pathological, molecular, and outcome levels. This may also extend to 
whether the TNM classification should even be the same for both 
diseases. 
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In the near future rational individualisation of radiation dose 
prescription will be possible. Current technology now allows the 
distribution of radiation dose to be tightly controlled and advances in 
our understanding of the biology of the disease will lead to 
individualisation of radiation dose delivery both within individual 
patients and between different patients. 
Functional imaging is at the present time the most likely candidate 
technology to influence our choice of individualising the dose 
distribution, however a number of unanswered questions remain 
before this can become a reality.  
This presentation will review the current state of this area of research 
and discuss likely forward directions of research. Clinical trials to 
evaluate these technologies will be discussed.  
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Radiofrequency ablation (RFA) is regarded as the primary ablative 
modality for local tumour destruction at most institutes.  It involves 
delivery of high-frequency, in the range of 375 to 500 kHz, alternating 
electrical current into the target tissue through a needle electrode.  
Electrical current passes back and forth through the body between the 
electrode and some grounding pads putting on the skin of the thighs.   
The high frequency of alternating current causes rapid movement of 
the ions or charged molecules within the cells in the tissue 
surrounding the electrode.  Heat is produced by friction during the 
rapid movement of these molecules. Temperature in excess of 50 °C 
produces coagulative necrosis.  A 2 to 5 cm spherical thermal injury 
can be produced with each ablation, depending on the design of the 
needle electrode. 
The main aim of thermal tumour ablation therapy is to destroy an 
entire tumour, with a 1 cm margin, in a minimally invasive fashion 
without damaging adjacent vital structures.  Each ablation requires 
exact placement of electrode in the tumour.  Any radiofrequency 
needle electrodes can be inserted percutaneously, under laparoscopic 
guidance or during laparotomy.  With percutaneous approach, the 
electrodes can be placed under sonographic, CT, or MR guidance.  
The major complications associated with RFA occur in 2.2–3.1% of 
patients. The minor complication rate ranges from 5% to 8.9%. 
Complications are divided into 3 different types: thermal damage 
(gastrointestinal perforation, biliary stenosis, cardiac tamponade and 
grounding pad burns), mechanical complications (injuries to bile ducts 
and vessels, tumour seeding and hemorrhage), and septic 
complications (abscess and peritonitis). Treatment of lesions adjacent 
(< 1 cm) to the hepatic hilum increases the risk of thermal injury of 
the major biliary tract and represents a relative contraindication to 
RFA. Thermal ablation of lesions adjacent to hepatic vessels increases 
the risk of incomplete treatment of the neoplastic tissue close to the 
vessel due to heat loss or heat sink effect. 
From the recent data on long-term survival of nonsurgical patients 
(due to comorbidity, patient refusal or unfavourable anatomy) with 
colorectal liver metastases (CRLM) who underwent RFA, the 5-year 
survival rate ranges 24–44%. These figures are substantially higher 
than those obtained with any chemotherapy regimens and provide 
indirect evidence that RFA therapy improves survival in patients with 
limited hepatic metastatic disease. 
Currently, liver resection (LR) is regarded as the gold standard 
treatment for resectable CRLM. One of the greatest criticisms for the 
utilization of RFA for treatment of CRLM has been a concern of high 
local recurrence at the RFA site. Local recurrence rates after RFA in 
the literature have been quite variable and range from 4% to 55%.  A 
recent meta-analysis found the overall local recurrence rate to be 
14.7%. 
Multiple studies have been published comparing RFA to LR for 
treatment of CRLM. In a recent published meta-analysis, 3-year  and 
5-year disease free survival as well as 3- year and 5-year overall 
survival are significantly higher in the LR group.  
Based on these retrospective reports, several authors have concluded 
that RFA is not equivalent to surgical resection and therefore should 
not be used to treat lesions that are otherwise resectable. Due to the 
retrospective nature of these studies, and the significant bias in 
patient selection, these results are difficult to interpret and the role 
of RFA remains biased. In addition, these retrospective studies are not 
randomized. 
The use of RFA does not prevent simultaneous or subsequent use of 
other, potentially complementary, treatments. Combining with other 
treatment modality is probably the future direction for RFA in the 
treatment of CRLM. 
There is limited data on the use of RFA in treating hepatic metastases 
from non CRLM.  The conclusion from those published 
studies employing RFA to treat non CRLM is that RFA is regarded as an 
adjunct to resection and unresectable lesions that demonstrate 
positive response after chemotherapy.   
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The present evidence for local ablation of liver oligo-metastases is 
limited. No randomized controlled trial has ever proven the efficacy 
of local ablation on survival, and the evidence is even poorer when it 
comes to comparisons of the different ablation methods. Surgical 
resection has by tradition been the preferred therapy for liver oligo-
metastases and radiofrequency ablation (RFA) is frequently used for 
treatment of inoperable patients. Stereotactic body radiation therapy 
(SBRT) is most often number three in line and has been used for 
therapy of medical inoperable patients and patients who are not 
amendable for surgery or RFA for technical reasons. These reasons are 
most often related to size of the metastases or the anatomical 
distribution in the liver. Where SBRT has been standard of care in 
therapy of patients with limited stage non-small cell cancer and 
lungmetastases for some time, the introduction of SBRT in the 
treatment of tumors in the liver has been characterized by hesitation.  
A number of retrospective and few prospective studies have been 
published on SBRT for liver metastases. In general, studies are 
characterized by considerably heterogeneity concerning patient 
selection. Retrospective studies often include a variety of tumor types 
with variability of number and size of the metastases and this 
translates into a broad variability in outcome. The most frequent 
tumor type investigated is colorectal carcinoma (CRC) metastases, but 
there are studies including almost all tumor types. Some studies show 
that survival outcomes are not different for CRC and non-CRC 
patients. Most studies demonstrate high local control rates ranging 80-
90% in SBRT for liver metastases. Treatment techniques, doses and 
fractionation varies between the studies, but an effect of dose 
escalation on the local control is fairly consistent. It is generally 
accepted that when using a 3 fraction schedule, the prescription dose 
should be at least 48 Gy.  
The morbidity after SBRT for liver metastases is mild to moderate. 
Most often it is limited to temporary abdominal wall pain, rib fracture 
and erythema. Severe morbidity related to exposure of the stomach or 
bowel and hepatic failure due to radiation hepatitis, a few being 
fatal, have been reported. 
Novel radiotherapy techniques have contributed to the improved 
precision in delivery of largeradiation doses to defined targets by 
